Cbas® heparin surface incorporates carmeda heparin manufactured from heparin sodium api, which is covalently bound to the device surface and is essentially non-eluting.Patient weight was not made available.(b)(4).During same procedure, three gore® viabahn® endoprosthesis with heparin bioactive surface (vsx device) were overlapped and implanted as one unit, from the superficial femoral to popliteal artery (tibio-peroneal trunk).Additional device lot/serial#: (b)(4); udi#: (b)(4) and lot/serial#: (b)(4); udi#: (b)(4).(b)(4).W.L.Gore & associates, inc.(gore) is submitting this report to comply with 21 c.F.R.Part 803, the medical device reporting regulation.This report is based upon information obtained by gore, which the company may not have been able to fully investigate or verify prior to the date the report was required by the fda.Blank fields present on this report include required fields and fields determined to be not applicable.Blank required fields indicate that the information was not provided, was deemed unavailable or was not applicable.This report does not constitute an admission or a conclusion by fda, gore, or its associates that the device, gore or its associates caused or contributed to the event described in the report.In particular, this report does not constitute a legal admission by anyone that the product described in this report has any defects or has malfunctioned, as defined from a legal standpoint.These words are included in the report and are fixed items for selection created by the fda, to categorize the type of event solely for the purpose of reporting pursuant to part 803.This statement should be included with any information or report disclosed to the public under the freedom of information act.
|
The following was reported to gore: on (b)(6) 2022, a patient presented for treatment due to a popliteal artery aneurysm.As reported, the patient had only one run off vessel to the foot.During this treatment, three gore® viabahn® endoprosthesis with heparin bioactive surface (vsx device) were overlapped and implanted as one unit, from the superficial femoral to popliteal artery (tibio-peroneal trunk).The sequence of device implantation was not specified.As reported, the vsx devices thrombosed within 24 hours post-procedure.A bypass procedure was required for the occluded device(s).The vsx devices remain implanted.The patient tolerated the procedure and is reported to recovering well.The physician stated the patient had only a single vessel run off prior to the procedure and this likely contributed to the device thrombosis.
|